Genmab — Marts 2025
-
Nu skal jeg ikke kloge i, hvad Abbvie har af intention med sit sagsanlæg. - Men kan et sagsanlæg der henvender sig til et stof der er så lang fremme i udviklingen - det kan Abbvie da vel ikke forsinke med et sådan sagsanlæg?..... Hvis der er noget hold i anklagen, så burde det vel være sådan at Genmab skal betale royalties til Abbvie af det eventuelle salg..... Det lyder helt forkert for mig at Abbvie kan stoppe/forsinke processen
-
Men de fleste ser anderledes på det. Aktien er ned 4% på en pæn positiv dag. Herinde begynder man så at drømme om at nu vil AbbVie pga dette købe Genmab til en saftig overpris, nu da den rolle ikke mere kan tildeles JNJ
-
Keep dreaming
-
Abbvie køber Immunogen 30. november 2023 https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field på SITC 3. november offentliggør Profound data fra Rina-S som de nok burde have været opmærksom på https://www.biospace.com/profoundbio-presents-promising-data-on-adc-programs-including-early-clinical-results-of-rinatabart-sesutecan-in-ovarian-and-endometrial-cancers-at-sitc-2023
-
Abbvies opfølger IMGN151 er i fase 1 siden december 2022 og har en DAR på 3,5 med deres payload DM21 https://aacrjournals.org/cancerres/article/80/16_Supplement/2890/642251/Abstract-2890-IMGN151-A-next-generation-folate Rina-S har DAR 6 med topoisomerase 1 inhibitor som payload. Hvilket stof der er bedst må tiden vise. Jeg har ikke fundet data på patienter fra IMGN151.
-
Correct DAR8 - Rina-S is an ADC comprised of a folate receptor-alpha-directed antibody conjugated to sesutecan, ProfoundBio’s novel, proprietary hydrophilic exatecan-based linker-drug, LD038, at a homogeneous drug-to-antibody ratio (DAR) of 8. Exatecan is a highly potent, membrane permeable topoisomerase-1 inhibitor with strong bystander effect that has been extensively studied as a small molecule anticancer agent. Sesutecan is a highly hydrophilic stable, cleavable linker designed to mask the
-
US20240207429A1 - Linkers, drug linkers and conjugates thereof and methods of using the same - Google Patents
The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.
(patents.google.com)
-
Rova-T: the story of AbbVie’s multi-billion dollar failure -I'll have another look at this story tomorrow, but maybe this is also about AbbVie having a grudge with former Stemcentrx employees... https://www.science.org/content/blog-post/last-stemcentrx
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind